Bicycle Therapeutics PLC at Piper Sandler Healthcare Conference Transcript
Good morning, everyone. My name is Ted Tenthoff. I'm a senior biotech analyst at Piper Sandler, and thank you for joining us for this year's in-person Healthcare Conference.
Before I begin, I am required to point out certain disclosures regarding the relationship between Piper Sandler and Bicycle, our next presenting company, that are located at the back of the room and also at the registration desk. So Bicycle is developing a novel class of bi-cyclic peptides, aptly called Bicycles, to treat cancer and a range of other diseases. The company is in the clinic with multiple Bicycle Toxin Conjugates or BTCs. And now also tumor-targeted immune cell agonists or TICAs for immuno-oncology.
The company has partnerships with Genentech, Ionis, Oxurion, AstraZeneca. And here with us today is Chief Scientific Officer, Nick Keen; Chief Medical Officer, Dominic Smethurst; and also CFO, Lee Kalowski. Guys, thanks for being with us.
Questions & Answers
So Nick, maybe you
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
